FOXF1 Gene Therapy Restores Intervertebral Discs After Injury

Disc degeneration: Are engineered extracellular vesicles (eEVs) loaded with FOXF1 the key to spinal rejuvenation and treatment of chronic low back pain?

Chronic low back pain (LBP) has become a global epidemic, causing disability and impairing the quality of life for millions of people.
With the aging population and the opioid crisis, the problem is only worsening.

The main cause of LBP is intervertebral disc (IVD) degeneration.
The IVD serves as a unique joint, compressing between the vertebrae of the spine and absorbing shock. With age, discs degenerate, losing moisture and elasticity, and become more prone to injury.

A groundbreaking new study offers new hope for LBP sufferers.
Researchers have developed a new gene therapy using engineered extracellular vesicles (eEVs), tiny nano-carriers secreted by cells, to deliver a gene called FOXF1 to damaged discs.

FOXF1 is a protein essential for normal disc development. It plays an important role in maintaining disc structure, function, and regenerative capacity.
Previous studies have shown that FOXF1 can reprogram diseased disc cells and promote tissue regeneration.

In this study, researchers injected engineered extracellular vesicles (eEVs) loaded with FOXF1 into damaged discs of mice.
The results were remarkable:

• Significant reduction in back pain in treated mice, with the effect on pain behavior being sex-specific and not uniform between males and females.
• Significant restoration of disc structure and function.
• Significant increase in disc height, tissue hydration, proteoglycan content, and mechanical properties.

This is the first study to successfully demonstrate restoration of disc function while reducing back pain in an animal model of LBP.

The study offers several significant advantages:

• Non-viral treatment: Unlike traditional gene therapies that use viruses to deliver genes, engineered extracellular vesicles are non-viral and therefore safer for use.
• Targeted delivery: Engineered extracellular vesicles can be directed to specific discs, ensuring the treatment reaches the right location.
• Potential for treating additional disorders: Engineered extracellular vesicles loaded with other genes could be used to treat other painful musculoskeletal disorders.

It is important to note that this is a preliminary study, and further clinical trials are needed to confirm the treatment's efficacy in humans.
However, the promising results offer great hope for LBP sufferers and those with other painful musculoskeletal disorders.

Engineered extracellular vesicles loaded with FOXF1 may be the key to rejuvenating damaged discs, reducing chronic low back pain, and improving the quality of life for millions of people worldwide.

References: https://www.sciencedirect.com/science/article/pii/S0142961224000966?via%3Dihub